Patients, payers, and providers all view value in different ways, and they all need to be taken into account in value frameworks, said Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow.
Patients, payers, and providers all view value in different ways, and they all need to be taken into account in value frameworks, said Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow.
Transcript (slightly modified)
How do different healthcare stakeholders view value differently?
Different stakeholders view value differently in a few ways. Patients, for instance, when they think about value, they are thinking about “how does this therapy help me achieve my life objectives?” Payers, on the other hand, are think about value and then designing coverage policies accordingly in terms of how to give patients access to the therapies that meet those life objectives, but they also have to balance that with their fiduciary responsibility.
Essentially, this is an issue of balancing patient access and costs. Patients have a bit of a more individual viewpoint when thinking about value, whereas payers have to think on a more population based level.
How can these differing viewpoints be taken into account as new value assessment frameworks are created?
Different viewpoints can be taken into account as more value assessment frameworks are created by tailoring them to the specific end-user. Secondly, by making sure they represent a range of values that account for the spectrum of preferences.
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen